Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaboration agreements, milestone payments, and license fees. Key therapeutic areas include endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, and insomnia.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Total Revenues | $1.2 million | $39.2 million |
| Net Loss | $(207.3) million | $(107.2) million |
| Loss Per Share (Basic/Diluted) | $(5.45) | $(2.84) |
| Research & Development Expenses | $82.0 million | $97.7 million |
| Cash, Cash Equivalents & Short-term Investments | $179.4 million | $182.6 million |
| Working Capital | $153.0 million | $173.5 million |
| Accumulated Deficit | $(614.7) million | $(407.4) million |
| Long-term Debt | $0 | $49.2 million |
Note: The 2007 results include a significant non-cash asset impairment charge of $94.0 million related to a prepaid royalty asset.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped 97% to $1.2 million from $39.2 million in 2006. This decrease is primarily due to the termination of the collaboration agreement with Pfizer in December 2006, which had generated significant milestone and sales force allowance revenue in the prior year.
- Increased Net Loss: Net loss doubled to $207.3 million from $107.2 million. The increase is driven largely by the $94.0 million non-cash impairment charge on the prepaid royalty asset for indiplon and lower revenues.
- Debt Reduction: The company retired $47.7 million in mortgage debt in December 2007 through a sale-leaseback transaction of its corporate facility.
- Restructuring: In December 2007, the company initiated a restructuring program reducing staff by approximately 125 employees, resulting in a $6.9 million charge.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Indiplon Status: On December 12, 2007, the FDA issued an "Approvable" letter for indiplon 5mg and 10mg capsules but requested additional studies (elderly clinical trial, safety study vs. marketed product, and pregnancy study) before final approval. The 15mg tablet remains "Not Approvable." The company has ceased U.S. clinical development and pre-commercialization activities pending FDA discussions.
- Liquidity: Management believes existing capital resources ($179.4 million in cash/investments) plus future collaboration payments will satisfy funding requirements for at least the next 12 months.
- Future Revenue: Revenues are expected to increase in 2008 compared to 2007, primarily due to the new exclusive license agreement with Dainippon Sumitomo Pharma Co. Ltd. (DSP) for indiplon in Japan, which included a $20 million upfront payment.
Risks and Contingencies
- Regulatory Uncertainty: Significant uncertainty remains regarding the approval and commercialization of indiplon, the company's most advanced asset. Failure to meet FDA requirements could result in the product never being approved.
- Litigation: The company is facing a consolidated securities class action lawsuit and a shareholder derivative lawsuit alleging false statements regarding the progress of indiplon. The impact on financial results is currently not estimable.
- Profitability: The company has a history of losses and does not expect to be profitable in 2008. Continued losses may require additional equity or debt financing, which could be dilutive or restrictive.
Investor Verification Checklist
- Indiplon FDA Requirements: Verify the specific scope and cost of the additional studies requested by the FDA in the December 2007 "Approvable" letter and the timeline for their completion.
- Asset Impairment: Confirm the valuation methodology used for the $94.0 million impairment of the prepaid royalty asset and the likelihood of future recovery.
- Litigation Exposure: Monitor the status of the securities class action lawsuit and the shareholder derivative suit, including the outcome of the motion to dismiss scheduled for April 2008.
- Collaboration Milestones: Review the terms of the DSP agreement to understand the conditions for the potential $115 million in future milestone payments.
- Cash Burn Rate: Assess the company's operating cash burn rate against its $179.4 million cash balance to determine the runway before additional financing is required.